References
- Marano M, Bottaro G, Goffredo B, et al. Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis. Eur J ClinPharmacol. 2016;72:247–248.
- Ramaswami A, Rosen DJ, Chu J, et al. Fulminant liver failure in a child with β-thalassemia on deferasirox: a case report. J Pediatr Hematol Oncol. 2017;39:235–237.
- Wei HY, Yang CP, Cheng CH, et al. Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months. Transfusion. 2011;51:949–954.
- Polson J, Lee WM. AASLD position paper: the management of acute liver failure. American Association for the Study of Liver Disease. Hepatology. 2005;41:1179–1197.
- Häberle J. Clinical and biochemical aspects of primary and secondary hyperammonemic disorders. Arch Biochem Biophys. 2013;536:101–108.